You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Prophylaxis and treatment against Kp: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Vanessa Arato.

Klebsiella pneumoniae (Kp) is an opportunistic pathogen and the leading cause of healthcare-associated infections, mostly affecting subjects with compromised immune systems or suffering from concurrent bacterial infections. However, the dramatic increase in hypervirulent strains and the emergence of new multidrug-resistant clones resulted in Kp occurrence among previously healthy people and in increased morbidity and mortality, including neonatal sepsis and death across low- and middle-income countries. As a consequence, carbapenem-resistant and extended spectrum β-lactamase-producing Kp have been prioritized as a critical anti-microbial resistance threat by the World Health Organization and this has renewed the interest of the scientific community in developing a vaccine as well as treatments alternative to the now ineffective antibiotics. Capsule polysaccharide is the most important virulence factor of Kp and plays major roles in the pathogenesis but its high variability (more than 100 different types have been reported) makes the identification of a universal treatment or prevention strategy very challenging. However, less variable virulence factors such as the O-Antigen, outer membrane proteins as fimbriae and siderophores might also be key players in the fight against Kp infections.

  • Klebsiella pneumoniae
  • anti-microbial resistance
  • vaccines
  • monoclonal antibodies
Please wait, diff process is still running!

References

  1. Bagley, S.T. Habitat association of Klebsiella species. Infect. Control. 1985, 6, 52–58.
  2. Brisse, S.; Verhoef, J. Phylogenetic diversity of Klebsiella pneumoniae and Klebsiella oxytoca clinical isolates revealed by randomly amplified polymorphic DNA, gyrA and parC genes sequencing and automated ribotyping. Int. J. Syst. Evol. Microbiol. 2001, 51, 915–924.
  3. Long, S.W.; Linson, S.E.; Ojeda Saavedra, M.; Cantu, C.; Davis, J.J.; Brettin, T.; Olsen, R.J. Whole-Genome Sequencing of Human Clinical Klebsiella pneumoniae Isolates Reveals Misidentification and Misunderstandings of Klebsiella pneumoniae, Klebsiella variicola, and Klebsiella quasipneumoniae. mSphere 2017, 2, 290.
  4. Diancourt, L.; Passet, V.; Verhoef, J.; Grimont, P.A.; Brisse, S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J. Clin. Microbiol. 2005, 43, 4178–4182.
  5. Bialek-Davenet, S.; Criscuolo, A.; Ailloud, F.; Passet, V.; Jones, L.; Delannoy-Vieillard, A.S.; Garin, B.; Le Hello, S.; Arlet, G.; Nicolas-Chanoine, M.H.; et al. Genomic definition of hypervirulent and multidrug-resistant Klebsiella pneumoniae clonal groups. Emerg Infect. Dis. 2014, 20, 1812–1820.
  6. Holt, K.E.; Wertheim, H.; Zadoks, R.N.; Baker, S.; Whitehouse, C.A.; Dance, D.; Jenney, A.; Connor, T.R.; Hsu, L.Y.; Severin, J.; et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc. Natl. Acad. Sci. USA 2015, 112, E3574–E3581.
  7. Wyres, K.L.; Holt, K.E. Klebsiella pneumoniae Population Genomics and Antimicrobial-Resistant Clones. Trends Microbiol. 2016, 24, 944–956.
  8. Wyres, K.L.; Hawkey, J.; Hetland, M.A.K.; Fostervold, A.; Wick, R.R.; Judd, L.M.; Hamidian, M.; Howden, B.P.; Lohr, I.H.; Holt, K.E. Emergence and rapid global dissemination of CTX-M-15-associated Klebsiella pneumoniae strain ST307. J. Antimicrob. Chemother. 2019, 74, 577–581.
  9. Shi, Q.; Lan, P.; Huang, D.; Hua, X.; Jiang, Y.; Zhou, J.; Yu, Y. Diversity of virulence level phenotype of hypervirulent Klebsiella pneumoniae from different sequence type lineage. BMC Microbiol. 2018, 18, 94.
  10. Lin, J.C.; Koh, T.H.; Lee, N.; Fung, C.P.; Chang, F.Y.; Tsai, Y.K.; Ip, M.; Siu, L.K. Genotypes and virulence in serotype K2 Klebsiella pneumoniae from liver abscess and non-infectious carriers in Hong Kong, Singapore and Taiwan. Gut Pathog. 2014, 6, 21.
  11. Wyres, K.L.; Lam, M.M.C.; Holt, K.E. Population genomics of Klebsiella pneumoniae. Nat. Rev. Microbiol. 2020, 18, 344–359.
  12. Follador, R.; Heinz, E.; Wyres, K.L.; Ellington, M.J.; Kowarik, M.; Holt, K.E.; Thomson, N.R. The diversity of Klebsiella pneumoniae surface polysaccharides. Microb. Genom. 2016, 2, e000073.
  13. Wyres, K.L.; Wick, R.R.; Gorrie, C.; Jenney, A.; Follador, R.; Thomson, N.R.; Holt, K.E. Identification of Klebsiella capsule synthesis loci from whole genome data. Microb. Genom. 2016, 2, e000102.
  14. Patro, L.P.P.; Sudhakar, K.U.; Rathinavelan, T. K-PAM: A unified platform to distinguish Klebsiella species K- and O-antigen types, model antigen structures and identify hypervirulent strains. Sci. Rep. 2020, 10, 16732.
  15. Choi, M.; Hegerle, N.; Nkeze, J.; Sen, S.; Jamindar, S.; Nasrin, S.; Sen, S.; Permala-Booth, J.; Sinclair, J.; Tapia, M.D.; et al. The Diversity of Lipopolysaccharide (O) and Capsular Polysaccharide (K) Antigens of Invasive Klebsiella pneumoniae in a Multi-Country Collection. Front. Microbiol. 2020, 11, 1249.
  16. Pennini, M.E.; De Marco, A.; Pelletier, M.; Bonnell, J.; Cvitkovic, R.; Beltramello, M.; Cameroni, E.; Bianchi, S.; Zatta, F.; Zhao, W.; et al. Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae. Nat. Commun. 2017, 8, 1991.
  17. Amako, K.; Meno, Y.; Takade, A. Fine structures of the capsules of Klebsiella pneumoniae and Escherichia coli K1. J. Bacteriol. 1988, 170, 4960–4962.
  18. Martin, R.M.; Bachman, M.A. Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae. Front. Cell Infect. Microbiol. 2018, 8, 4.
  19. Pan, Y.J.; Lin, T.L.; Lin, Y.T.; Su, P.A.; Chen, C.T.; Hsieh, P.F.; Hsu, C.R.; Chen, C.C.; Hsieh, Y.C.; Wang, J.T. Identification of capsular types in carbapenem-resistant Klebsiella pneumoniae strains by wzc sequencing and implications for capsule depolymerase treatment. Antimicrob. Agents Chemother. 2015, 59, 1038–1047.
  20. Patro, L.P.P.; Rathinavelan, T. Targeting the Sugary Armor of Klebsiella Species. Front. Cell Infect. Microbiol. 2019, 9, 367.
  21. Rahn, A.; Drummelsmith, J.; Whitfield, C. Conserved organization in the cps gene clusters for expression of Escherichia coli group 1K antigens: Relationship to the colanic acid biosynthesis locus and the cps genes from Klebsiella pneumoniae. J. Bacteriol. 1999, 181, 2307–2313.
  22. Sachdeva, S.; Palur, R.V.; Sudhakar, K.U.; Rathinavelan, T. E. coli Group 1 Capsular Polysaccharide Exportation Nanomachinary as a Plausible Antivirulence Target in the Perspective of Emerging Antimicrobial Resistance. Front. Microbiol. 2017, 8, 70.
  23. Whitfield, C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu. Rev. Biochem. 2006, 75, 39–68.
  24. Shu, H.Y.; Fung, C.P.; Liu, Y.M.; Wu, K.M.; Chen, Y.T.; Li, L.H.; Liu, T.T.; Kirby, R.; Tsai, S.F. Genetic diversity of capsular polysaccharide biosynthesis in Klebsiella pneumoniae clinical isolates. Microbiology 2009, 155, 4170–4183.
  25. Fung, C.P.; Chang, F.Y.; Lee, S.C.; Hu, B.S.; Kuo, B.I.; Liu, C.Y.; Ho, M.; Siu, L.K. A global emerging disease of Klebsiella pneumoniae liver abscess: Is serotype K1 an important factor for complicated endophthalmitis? Gut 2002, 50, 420–424.
  26. Struve, C.; Roe, C.C.; Stegger, M.; Stahlhut, S.G.; Hansen, D.S.; Engelthaler, D.M.; Andersen, P.S.; Driebe, E.M.; Keim, P.; Krogfelt, K.A. Mapping the Evolution of Hypervirulent Klebsiella pneumoniae. mBio 2015, 6, e00630.
  27. Pomakova, D.K.; Hsiao, C.B.; Beanan, J.M.; Olson, R.; MacDonald, U.; Keynan, Y.; Russo, T.A. Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: An emerging and under-recognized pathogenic variant. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 981–989.
  28. Nassif, X.; Fournier, J.M.; Arondel, J.; Sansonetti, P.J. Mucoid phenotype of Klebsiella pneumoniae is a plasmid-encoded virulence factor. Infect. Immun. 1989, 57, 546–552.
  29. Russo, T.A.; Olson, R.; Fang, C.T.; Stoesser, N.; Miller, M.; MacDonald, U.; Hutson, A.; Barker, J.H.; La Hoz, R.M.; Johnson, J.R. Identification of Biomarkers for Differentiation of Hypervirulent Klebsiella pneumoniae from Classical K. pneumoniae. J. Clin. Microbiol. 2018, 56, 18.
  30. Yu, F.; Lv, J.; Niu, S.; Du, H.; Tang, Y.W.; Pitout, J.D.D.; Bonomo, R.A.; Kreiswirth, B.N.; Chen, L. Multiplex PCR Analysis for Rapid Detection of Klebsiella pneumoniae Carbapenem-Resistant (Sequence Type 258 [ST258] and ST11) and Hypervirulent (ST23, ST65, ST86, and ST375) Strains. J. Clin. Microbiol. 2018, 56, 731.
  31. Yu, W.L.; Ko, W.C.; Cheng, K.C.; Lee, C.C.; Lai, C.C.; Chuang, Y.C. Comparison of prevalence of virulence factors for Klebsiella pneumoniae liver abscesses between isolates with capsular K1/K2 and non-K1/K2 serotypes. Diagn Microbiol. Infect. Dis. 2008, 62, 1–6.
  32. Shon, A.S.; Bajwa, R.P.; Russo, T.A. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: A new and dangerous breed. Virulence 2013, 4, 107–118.
  33. Clarke, B.R.; Ovchinnikova, O.G.; Kelly, S.D.; Williamson, M.L.; Butler, J.E.; Liu, B.; Wang, L.; Gou, X.; Follador, R.; Lowary, T.L.; et al. Molecular basis for the structural diversity in serogroup O2-antigen polysaccharides in Klebsiella pneumoniae. J. Biol. Chem. 2018, 293, 4666–4679.
  34. Trautmann, M.; Ruhnke, M.; Rukavina, T.; Held, T.K.; Cross, A.S.; Marre, R.; Whitfield, C. O-antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections. Clin. Diagn. Lab. Immunol. 1997, 4, 550–555.
  35. Hansen, D.S.; Mestre, F.; Alberti, S.; Hernandez-Alles, S.; Alvarez, D.; Domenech-Sanchez, A.; Gil, J.; Merino, S.; Tomas, J.M.; Benedi, V.J. Klebsiella pneumoniae lipopolysaccharide O typing: Revision of prototype strains and O-group distribution among clinical isolates from different sources and countries. J. Clin. Microbiol. 1999, 37, 56–62.
  36. Kalynych, S.; Morona, R.; Cygler, M. Progress in understanding the assembly process of bacterial O-antigen. FEMS Microbiol. Rev. 2014, 38, 1048–1065.
  37. Regue, M.; Izquierdo, L.; Fresno, S.; Pique, N.; Corsaro, M.M.; Naldi, T.; De Castro, C.; Waidelich, D.; Merino, S.; Tomas, J.M. A second outer-core region in Klebsiella pneumoniae lipopolysaccharide. J. Bacteriol. 2005, 187, 4198–4206.
  38. Fresno, S.; Jimenez, N.; Canals, R.; Merino, S.; Corsaro, M.M.; Lanzetta, R.; Parrilli, M.; Pieretti, G.; Regue, M.; Tomas, J.M. A second galacturonic acid transferase is required for core lipopolysaccharide biosynthesis and complete capsule association with the cell surface in Klebsiella pneumoniae. J. Bacteriol. 2007, 189, 1128–1137.
  39. Okuda, S.; Sherman, D.J.; Silhavy, T.J.; Ruiz, N.; Kahne, D. Lipopolysaccharide transport and assembly at the outer membrane: The PEZ model. Nat. Rev. Microbiol. 2016, 14, 337–345.
  40. Clarke, B.R.; Whitfield, C. Molecular cloning of the rfb region of Klebsiella pneumoniae serotype O1:K20: The rfb gene cluster is responsible for synthesis of the D-galactan I O polysaccharide. J. Bacteriol. 1992, 174, 4614–4621.
  41. Kelly, R.F.; Perry, M.B.; MacLean, L.L.; Whitfield, C. Structures of the O-antigens of Klebsiella serotypes 02 (2a,2e), 02 (2a,2e,2h), and 02 (2a,2f,2g), members of a family of related D-galactan O-antigens in Klebsiella spp. Innate Immun. 1995, 2, 131–140.
  42. Kelly, R.F.; Severn, W.B.; Richards, J.C.; Perry, M.B.; MacLean, L.L.; Tomás, J.M.; Merino, S.; Whitfield, C. Structural variation in the O-specific polysaccharides of Klebsiella pneumoniae serotype O1 and O8 lipopolysaccharide: Evidence for clonal diversity in rfb genes. Mol. Microbiol. 1993, 10, 615–625.
  43. Hsieh, P.F.; Wu, M.C.; Yang, F.L.; Chen, C.T.; Lou, T.C.; Chen, Y.Y.; Wu, S.H.; Sheu, J.C.; Wang, J.T. D-galactan II is an immunodominant antigen in O1 lipopolysaccharide and affects virulence in Klebsiella pneumoniae: Implication in vaccine design. Front. Microbiol. 2014, 5, 608.
  44. Prehm, P.; Jann, B.; Jann, K. The O9 antigen of Escherichia coli. Structure of the polysaccharide chain. Eur. J. Biochem. 1976, 67, 53–56.
  45. Jansson, P.E.e.a. Structural studies of the O-antigen polysaccharides of Klebsiella O5 and Escherichia coli O8. Carbohydr. Res. 1985, 145, 59–66.
  46. Greenfield, L.K.E.A. Biosynthesis of the polymannose lipopolysaccharide O-antigens from Escherichia coli serotypes O8 and O9a requires a unique combination of single- and multiple-active site mannosyltransferases. J. Biol. Chem. 2012, 287, 35078–35091.
  47. Hagelueken, G.E.A. Structure of WbdD: A bifunctional kinase and methyltransferase that regulates the chain length of the O antigen in Escherichia coli O9a. Mol. Microbiol. 2012, 86, 730–742.
  48. Vinogradov, E.E.A. Structures of lipopolysaccharides from Klebsiella pneumoniae. Eluicidation of the structure of the linkage region between core and polysaccharide O chain and identification of the residues at the non-reducing termini of the O chains. J. Biol. Chem. 2002, 277, 25070–25081.
  49. Rollenske, T.; Szijarto, V.; Lukasiewicz, J.; Guachalla, L.M.; Stojkovic, K.; Hartl, K.; Stulik, L.; Kocher, S.; Lasitschka, F.; Al-Saeedi, M.; et al. Cross-specificity of protective human antibodies against Klebsiella pneumoniae LPS O-antigen. Nat. Immunol. 2018, 19, 617–624.
  50. Duguid, J.P.; Smith, I.W.; Dempster, G.; Edmunds, P.N. Non-flagellar filamentous appendages (fimbriae) and haemagglutinating activity in Bacterium coli. J. Pathol. Bacteriol. 1955, 70, 335–348.
  51. Althouse, C.; Patterson, S.; Fedorka-Cray, P.; Isaacson, R.E. Type 1 fimbriae of Salmonella enterica serovar Typhimurium bind to enterocytes and contribute to colonization of swine in vivo. Infect. Immun. 2003, 71, 6446–6452.
  52. Johnson, J.G.; Murphy, C.N.; Sippy, J.; Johnson, T.J.; Clegg, S. Type 3 fimbriae and biofilm formation are regulated by the transcriptional regulators MrkHI in Klebsiella pneumoniae. J. Bacteriol. 2011, 193, 3453–3460.
  53. Allen, W.J.; Phan, G.; Waksman, G. Pilus biogenesis at the outer membrane of Gram-negative bacterial pathogens. Curr. Opin. Struct. Biol. 2012, 22, 500–506.
  54. Clegg, S.; Wilson, J.; Johnson, J. More than one way to control hair growth: Regulatory mechanisms in enterobacteria that affect fimbriae assembled by the chaperone/usher pathway. J. Bacteriol. 2011, 193, 2081–2088.
  55. Morrissey, B.; Leney, A.C.; Toste Rego, A.; Phan, G.; Allen, W.J.; Verger, D.; Waksman, G.; Ashcroft, A.E.; Radford, S.E. The role of chaperone-subunit usher domain interactions in the mechanism of bacterial pilus biogenesis revealed by ESI-MS. Mol. Cell Proteom. 2012, 11, 15289.
  56. Wu, C.C.; Huang, Y.J.; Fung, C.P.; Peng, H.L. Regulation of the Klebsiella pneumoniae Kpc fimbriae by the site-specific recombinase KpcI. Microbiology 2010, 156, 1983–1992.
  57. Di Martino, P.; Livrelli, V.; Sirot, D.; Joly, B.; Darfeuille-Michaud, A. A new fimbrial antigen harbored by CAZ-5/SHV-4-producing Klebsiella pneumoniae strains involved in nosocomial infections. Infect. Immun. 1996, 64, 2266–2273.
  58. Di Martino, P.; Sirot, D.; Joly, B.; Rich, C.; Darfeuille-Michaud, A. Relationship between adhesion to intestinal Caco-2 cells and multidrug resistance in Klebsiella pneumoniae clinical isolates. J. Clin. Microbiol. 1997, 35, 1499–1503.
  59. Brinton, C.C., Jr. The structure, function, synthesis and genetic control of bacterial pili and a molecular model for DNA and RNA transport in gram negative bacteria. Trans. N. Y. Acad. Sci. 1965, 27, 1003–1054.
  60. Zyla, D.S.; Prota, A.E.; Capitani, G.; Glockshuber, R. Alternative folding to a monomer or homopolymer is a common feature of the type 1 pilus subunit FimA from enteroinvasive bacteria. J. Biol. Chem. 2019, 294, 10553–10563.
  61. Busch, A.; Phan, G.; Waksman, G. Molecular mechanism of bacterial type 1 and P pili assembly. Philos. Trans. A Math. Phys. Eng. Sci. 2015, 373, 153.
  62. Lillington, J.; Geibel, S.; Waksman, G. Biogenesis and adhesion of type 1 and P pili. Biochim. Biophys. Acta 2014, 1840, 2783–2793.
  63. Firon, N.; Ashkenazi, S.; Mirelman, D.; Ofek, I.; Sharon, N. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect. Immun. 1987, 55, 472–476.
  64. Firon, N.; Ofek, I.; Sharon, N. Carbohydrate-binding sites of the mannose-specific fimbrial lectins of enterobacteria. Infect. Immun. 1984, 43, 1088–1090.
  65. Bernhard, W.; Gbarah, A.; Sharon, N. Lectinophagocytosis of type 1 fimbriated (mannose-specific) Escherichia coli in the mouse peritoneum. J. Leukoc. Biol. 1992, 52, 343–348.
  66. Sharon, N. Bacterial lectins, cell-cell recognition and infectious disease. FEBS Lett. 1987, 217, 145–157.
  67. Struve, C.; Bojer, M.; Krogfelt, K.A. Characterization of Klebsiella pneumoniae type 1 fimbriae by detection of phase variation during colonization and infection and impact on virulence. Infect. Immun. 2008, 76, 4055–4065.
  68. Rosen, D.A.; Pinkner, J.S.; Walker, J.N.; Elam, J.S.; Jones, J.M.; Hultgren, S.J. Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Infect. Immun. 2008, 76, 3346–3356.
  69. Jung, H.J.; Littmann, E.R.; Seok, R.; Leiner, I.M.; Taur, Y.; Peled, J.; van den Brink, M.; Ling, L.; Chen, L.; Kreiswirth, B.N.; et al. Genome-Wide Screening for Enteric Colonization Factors in Carbapenem-Resistant ST258 Klebsiella pneumoniae. mBio 2019, 10, 663.
  70. Young, T.M.; Bray, A.S.; Nagpal, R.K.; Caudell, D.L.; Yadav, H.; Zafar, M.A. Animal Model To Study Klebsiella pneumoniae Gastrointestinal Colonization and Host-to-Host Transmission. Infect. Immun. 2020, 88, 128.
  71. Allen, B.L.; Gerlach, G.F.; Clegg, S. Nucleotide sequence and functions of mrk determinants necessary for expression of type 3 fimbriae in Klebsiella pneumoniae. J. Bacteriol. 1991, 173, 916–920.
  72. Duguid, J.P. Fimbriae and adhesive properties in Klebsiella strains. J. Gen. Microbiol. 1959, 21, 271–286.
  73. Huang, Y.J.; Liao, H.W.; Wu, C.C.; Peng, H.L. MrkF is a component of type 3 fimbriae in Klebsiella pneumoniae. Res. Microbiol. 2009, 160, 71–79.
  74. Sebghati, T.A.; Korhonen, T.K.; Hornick, D.B.; Clegg, S. Characterization of the type 3 fimbrial adhesins of Klebsiella strains. Infect. Immun. 1998, 66, 2887–2894.
  75. Burmolle, M.; Bahl, M.I.; Jensen, L.B.; Sorensen, S.J.; Hansen, L.H. Type 3 fimbriae, encoded by the conjugative plasmid pOLA52, enhance biofilm formation and transfer frequencies in Enterobacteriaceae strains. Microbiology 2008, 154, 187–195.
  76. Ong, C.L.; Beatson, S.A.; McEwan, A.G.; Schembri, M.A. Conjugative plasmid transfer and adhesion dynamics in an Escherichia coli biofilm. Appl. Environ. Microbiol. 2009, 75, 6783–6791.
  77. Tarkkanen, A.M.; Allen, B.L.; Westerlund, B.; Holthofer, H.; Kuusela, P.; Risteli, L.; Clegg, S.; Korhonen, T.K. Type V collagen as the target for type-3 fimbriae, enterobacterial adherence organelles. Mol. Microbiol. 1990, 4, 1353–1361.
  78. Schroll, C.; Barken, K.B.; Krogfelt, K.A.; Struve, C. Role of type 1 and type 3 fimbriae in Klebsiella pneumoniae biofilm formation. BMC Microbiol. 2010, 10, 179.
  79. Boddicker, J.D.; Anderson, R.A.; Jagnow, J.; Clegg, S. Signature-tagged mutagenesis of Klebsiella pneumoniae to identify genes that influence biofilm formation on extracellular matrix material. Infect. Immun. 2006, 74, 4590–4597.
  80. Jagnow, J.; Clegg, S. Klebsiella pneumoniae MrkD-mediated biofilm formation on extracellular matrix- and collagen-coated surfaces. Microbiology 2003, 149, 2397–2405.
  81. Foroohimanjili, F.; Mirzaie, A.; Hamdi, S.M.M.; Noorbazargan, H.; Hedayati Ch, M.; Dolatabadi, A.; Rezaie, H.; Bishak, F.M. Antibacterial, antibiofilm, and antiquorum sensing activities of phytosynthesized silver nanoparticles fabricated from Mespilus germanica extract against multidrug resistance of Klebsiella pneumoniae clinical strains. J. Basic. Microbiol. 2020, 60, 216–230.
  82. Wilksch, J.J.; Yang, J.; Clements, A.; Gabbe, J.L.; Short, K.R.; Cao, H.; Cavaliere, R.; James, C.E.; Whitchurch, C.B.; Schembri, M.A.; et al. MrkH, a novel c-di-GMP-dependent transcriptional activator, controls Klebsiella pneumoniae biofilm formation by regulating type 3 fimbriae expression. PLoS Pathog. 2011, 7, e1002204.
  83. Rosen, D.A.; Twentyman, J.; Hunstad, D.A. High Levels of Cyclic Di-GMP in Klebsiella pneumoniae Attenuate Virulence in the Lung. Infect. Immun. 2018, 86, 647.
  84. Arato, V.; Gasperini, G.; Giusti, F.; Ferlenghi, I.; Scarselli, M.; Leuzzi, R. Dual role of the colonization factor CD2831 in Clostridium difficile pathogenesis. Sci. Rep. 2019, 9, 5554.
  85. Wu, D.C.; Zamorano-Sanchez, D.; Pagliai, F.A.; Park, J.H.; Floyd, K.A.; Lee, C.K.; Kitts, G.; Rose, C.B.; Bilotta, E.M.; Wong, G.C.L.; et al. Reciprocal c-di-GMP signaling: Incomplete flagellum biogenesis triggers c-di-GMP signaling pathways that promote biofilm formation. PLoS Genet. 2020, 16, e1008703.
  86. Zamorano-Sanchez, D.; Xian, W.; Lee, C.K.; Salinas, M.; Thongsomboon, W.; Cegelski, L.; Wong, G.C.L.; Yildiz, F.H. Functional Specialization in Vibrio cholerae Diguanylate Cyclases: Distinct Modes of Motility Suppression and c-di-GMP Production. mBio 2019, 10, 670.
  87. Miethke, M.; Marahiel, M.A. Siderophore-based iron acquisition and pathogen control. Microbiol. Mol. Biol. Rev. 2007, 71, 413–451.
  88. Neilands, J.B. Iron absorption and transport in microorganisms. Annu Rev. Nutr. 1981, 1, 27–46.
  89. Russo, T.A.; Marr, C.M. Hypervirulent Klebsiella pneumoniae. Clin. Microbiol. Rev. 2019, 32, 1128.
  90. Russo, T.A.; Olson, R.; Macdonald, U.; Metzger, D.; Maltese, L.M.; Drake, E.J.; Gulick, A.M. Aerobactin mediates virulence and accounts for increased siderophore production under iron-limiting conditions by hypervirulent (hypermucoviscous) Klebsiella pneumoniae. Infect. Immun. 2014, 82, 2356–2367.
  91. Hsieh, P.F.; Lin, T.L.; Lee, C.Z.; Tsai, S.F.; Wang, J.T. Serum-induced iron-acquisition systems and TonB contribute to virulence in Klebsiella pneumoniae causing primary pyogenic liver abscess. J. Infect. Dis. 2008, 197, 1717–1727.
  92. Choi, M.; Tennant, S.M.; Simon, R.; Cross, A.S. Progress towards the development of Klebsiella vaccines. Expert Rev. Vaccines 2019, 18, 681–691.
  93. Zurawski, D.V.; McLendon, M.K. Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens. Antibiotics 2020, 9, 155.
  94. Mizgerd, J.P.; Skerrett, S.J. Animal models of human pneumonia. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 294, L387–L398.
  95. Bengoechea, J.A.; Pessoa, J.S. Klebsiella pneumoniae infection biology: Living to counteract host defences. FEMS Microbiol. Rev. 2019, 43, 123–144.
  96. Berendt, R.F.; Magruder, R.D.; Frola, F.R. Treatment of Klebsiella pneumoniae respiratory tract infection of squirrel monkeys with aerosol administration of kanamycin. Am. J. Vet. Res. 1980, 41, 1492–1494.
  97. Berendt, R.F.; Knutsen, G.L.; Powanda, M.C. Nonhuman primate model for the study of respiratory Klebsiella pneumoniae infection. Infect. Immun. 1978, 22, 275–281.
  98. Micoli, F.; Costantino, P.; Adamo, R. Potential targets for next generation antimicrobial glycoconjugate vaccines. FEMS Microbiol. Rev. 2018, 42, 388–423.
  99. Cooper, J.M.; Rowley, D. Resistance to Klebsiella pneumoniae and the importance of two bacterial antigens. Aust. J. Exp. Biol. Med. Sci. 1982, 60, 629–641.
  100. Cryz, S.J.F.E.; Germanier, R. Protection against fatal Klebsiella pneumoniae burn wound sepsis by passive transfer of anticapsular polysaccharide. Infect. Immun. 1984, 45, 139–142.
  101. Cryz, S.J., Jr.; Furer, E.; Germanier, R. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans. J. Infect. Dis. 1985, 151, 665–671.
  102. Trautmann, M.; Cryz, S.J., Jr.; Sadoff, J.C.; Cross, A.S. A murine monoclonal antibody against Klebsiella capsular polysaccharide is opsonic in vitro and protects against experimental Klebsiella pneumoniae infection. Microb. Pathog. 1988, 5, 177–187.
  103. Cryz, S.J., Jr.; Mortimer, P.; Cross, A.S.; Furer, E.; Germanier, R. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. Vaccine 1986, 4, 15–20.
  104. Granstrom, M.; Wretlind, B.; Markman, B.; Cryz, S. Enzyme-linked immunosorbent assay to evaluate the immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. J. Clin. Microbiol. 1988, 26, 2257–2261.
  105. Cryz, S.J., Jr.; Mortimer, P.M.; Mansfield, V.; Germanier, R. Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development. J. Clin. Microbiol. 1986, 23, 687–690.
  106. Cryz, S.J., Jr.; Furer, E.; Sadoff, J.C.; Fredeking, T.; Que, J.U.; Cross, A.S. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J. Infect. Dis. 1991, 163, 1055–1061.
  107. Edelman, R.; Taylor, D.N.; Wasserman, S.S.; McClain, J.B.; Cross, A.S.; Sadoff, J.C.; Que, J.U.; Cryz, S.J. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Vaccine 1994, 12, 1288–1294.
  108. Donta, S.T.; Peduzzi, P.; Cross, A.S.; Sadoff, J.; Haakenson, C.; Cryz, S.J., Jr.; Kauffman, C.; Bradley, S.; Gafford, G.; Elliston, D.; et al. Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J. Infect. Dis. 1996, 174, 537–543.
  109. Zigterman, J.W.; van Dam, J.E.; Snippe, H.; Rotteveel, F.T.; Jansze, M.; Willers, J.M.; Kamerling, J.P.; Vliegenthart, J.F. Immunogenic properties of octasaccharide-protein conjugates derived from Klebsiella serotype 11 capsular polysaccharide. Infect. Immun. 1985, 47, 421–428.
  110. Seeberger, P.H.; Pereira, C.L.; Khan, N.; Xiao, G.; Diago-Navarro, E.; Reppe, K.; Opitz, B.; Fries, B.C.; Witzenrath, M. A Semi-Synthetic Glycoconjugate Vaccine Candidate for Carbapenem-Resistant Klebsiella pneumoniae. Angew Chem. Int. Ed. Engl. 2017, 56, 13973–13978.
  111. Feldman, M.F.; Bridwell, A.E.M.; Scott, N.E.; Vinogradov, E.; McKee, S.R.; Chavez, S.M.; Twentyman, J.; Stallings, C.L.; Rosen, D.A.; Harding, C.M. A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae. Proc. Natl. Acad. Sci. USA 2019, 116, 18655–18663.
  112. Diago-Navarro, E.; Motley, M.P.; Ruiz-Perez, G.; Yu, W.; Austin, J.; Seco, B.M.S.; Xiao, G.; Chikhalya, A.; Seeberger, P.H.; Fries, B.C. Novel, Broadly Reactive Anticapsular Antibodies against Carbapenem-Resistant Klebsiella pneumoniae Protect from Infection. mBio 2018, 9, 18.
  113. Trautmann, M.; Held, T.K.; Cross, A.S. O-antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections. Vaccine 2004, 22, 818–821.
  114. Clements, A.; Jenney, A.W.; Farn, J.L.; Brown, L.E.; Deliyannis, G.; Hartland, E.L.; Pearse, M.J.; Maloney, M.B.; Wesselingh, S.L.; Wijburg, O.L.; et al. Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections. Vaccine 2008, 26, 5649–5653.
  115. Chhibber, S.; Wadhwa, S.; Yadav, V. Protective role of liposome incorporated lipopolysaccharide antigen of Klebsiella pneumoniae in a rat model of lobar pneumonia. Jpn J. Infect. Dis. 2004, 57, 150–155.
  116. Chhibber, S.; Rani, M.; Vanashree, Y. Immunoprotective potential of polysaccharide-tetanus toxoid conjugate in Klebsiella pneumoniae induced lobar pneumonia in rats. Indian. J. Exp. Biol. 2005, 43, 40–45.
  117. Hegerle, N.; Choi, M.; Sinclair, J.; Amin, M.N.; Ollivault-Shiflett, M.; Curtis, B.; Laufer, R.S.; Shridhar, S.; Brammer, J.; Toapanta, F.R.; et al. Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa. PLoS ONE 2018, 13, e0203143.
  118. Harduin-Lepers, A. Glyco25, XXV International Symposium on Glycoconjugates. Glycoconj. J. 2019, 36, 267–397.
  119. Zhang, L.; Pan, C.; Feng, E.; Hua, X.; Yu, Y.; Wang, H.; Zhu, L. Biosynthesis of polysaccharide conjugate vaccines against Klebsiella pneumoniae serotype O2 strains. Sheng Wu Gong Cheng Xue Bao 2020, 36, 1899–1907.
  120. Cohen, T.S.; Pelletier, M.; Cheng, L.; Pennini, M.E.; Bonnell, J.; Cvitkovic, R.; Chang, C.S.; Xiao, X.; Cameroni, E.; Corti, D.; et al. Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4. JCI Insight 2017, 2, 774.
  121. Guachalla, L.M.; Stojkovic, K.; Hartl, K.; Kaszowska, M.; Kumar, Y.; Wahl, B.; Paprotka, T.; Nagy, E.; Lukasiewicz, J.; Nagy, G.; et al. Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3. Sci. Rep. 2017, 7, 6635.
  122. Lavender, H.; Jagnow, J.J.; Clegg, S. Klebsiella pneumoniae type 3 fimbria-mediated immunity to infection in the murine model of respiratory disease. Int. J. Med. Microbiol. 2005, 295, 153–159.
  123. Wang, Q.; Chang, C.S.; Pennini, M.; Pelletier, M.; Rajan, S.; Zha, J.; Chen, Y.; Cvitkovic, R.; Sadowska, A.; Heidbrink, T.J.; et al. Target-Agnostic Identification of Functional Monoclonal Antibodies Against Klebsiella pneumoniae Multimeric MrkA Fimbrial Subunit. J. Infect. Dis. 2016, 213, 1800–1808.
  124. Witkowska, D.; Mieszała, M.; Gamian, A.; Staniszewska, M.; Czarny, A.; Przondo-Mordarska, A.; Jaquinod, M.; Forest, E. Major structural proteins of type 1 and type 3 Klebsiella fimbriae are effective protein carriers and immunogens in conjugates as revealed from their immunochemical characterization. FEMS Immunol. Med. Microbiol. 2005, 45, 221–230.
  125. Zargaran, F.N.; Akya, A.; Rezaeian, S.; Ghadiri, K.; Lorestani, R.C.; Madanchi, H.; Safaei, S.; Rostamian, M. B Cell Epitopes of Four Fimbriae Antigens of Klebsiella pneumoniae: A Comprehensive In Silico Study for Vaccine Development. Int. J. Pept. Res. Ther. 2020, 134, 1–12.
  126. Dar, H.A.; Zaheer, T.; Shehroz, M.; Ullah, N.; Naz, K.; Muhammad, S.A.; Zhang, T.; Ali, A. Immunoinformatics-Aided Design and Evaluation of a Potential Multi-Epitope Vaccine against Klebsiella Pneumoniae. Vaccines 2019, 7, 88.
  127. Rodrigues, M.X.; Yang, Y.; de Souza, M.E.B., Jr.; do Carmo, S.J.; Bicalho, R.C. Development and evaluation of a new recombinant protein vaccine (YidR) against Klebsiella pneumoniae infection. Vaccine 2020, 38, 4640–4648.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback